Dr. Reddys Laboratories Ltd.

Dr. Reddys Laboratories is currently trading at Rs. 2476.80, up by 30.20 points or 1.23% from its previous closing of Rs. 2446.60 on the BSE.

The scrip opened at Rs. 2480.00 and has touched a high and low of Rs. 2600.05 and Rs. 2450.50 respectively. So far 13150 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2687.45 on 28-Sep-2018 and a 52 week low of Rs. 1888.00 on 21-May-2018.

Last one week high and low of the scrip stood at Rs. 2600.05 and Rs. 2332.10 respectively. The current market cap of the company is Rs. 41112.12 crore.

The promoters holding in the company stood at 26.79 %, while Institutions and Non-Institutions held 44.27% and 14.60 % respectively.

Dr. Reddy’s Laboratories has launched Colesevelam HCI Tablets, USP, a therapeutic equivalent generic version of WELCHOL (colesevelam HCI) Tablets in the United States market approved by the US Food and Drug Administration (USFDA).

The WELCHOL brand and generic had US sales of around $471 million MAT for the most recent twelve months ending in August 2018 according to IMS Health. Dr. Reddy's Colesevelam Hydrochloride Tablets is available in 625 mg with 180 count bottle size.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.